Tex. Health & Safety Code § 491.052 · Subchapter B. ACCESS TO INDIVIDUALIZED INVESTIGATIONAL TREATMENT
PATIENT ELIGIBILITY.
Text — Current through the 89th 2nd Called Legislative Session, 2025
A patient is eligible to access an individualized investigational treatment under this chapter if:
(1) the patient:
(A) has a life-threatening illness or severely debilitating illness;
(B) has considered all other treatment options currently approved by the United States Food and Drug Administration; and
(C) has given written informed consent for access to the treatment; and
(2) the patient's physician:
(A) attests to the patient's life-threatening illness or severely debilitating illness and the patient's eligibility under this section; and
(B) recommends the treatment for the patient based on analysis of the patient's genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products such as enzymes and other types of proteins, or metabolites.
Notes and commentary — not statutory text
History
Added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984), Sec. 1, eff. September 1, 2025.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/HS/htm/HS.491.V3.htm
- Text hash
- sha256 c99c6e4ac15d34e3a2c00287b8b65aabef6ad70112784b387485894c59af9080
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
- the Legislature enacted more than one unit numbered 491.052; this is the one the Council prints in hs.491.v3.htm
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.